The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant melanomas an gliomas displayed strong cytoplasmic and nuclear immunoreactivity. Most other malignant cells were negative.
Most malignancies were negative. Strong cytoplasmic and membranous positivity was observed in malignant melanomas, gliomas and several testicular cancers as well as a few cases of squamous cell carcinomas and urothelial cancer.
Most malignant tissues were negative. Malignant melanomas and several cases of malignant gliomas exhibited moderate to strong cytoplasmic immunoreactivity.
Melanomas showed moderate to strong cytoplasmic positivity. A few cases of gliomas, endometrial and lung cancers displayed moderate positivity. Remaining cancer tissues were negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data